Search Close Search
Search Close Search
Page Menu

Roberto Bomprezzi, MD, PhD, Associate Professor of neurology

Roberto Bomprezzi, MD, PhD, Associate Professor of neurology

Roberto Bomprezzi, MD, PhD
Associate Clinical Director
Neuroimmunology, MS Center

Academic Appointment:
Roberto Bomprezzi MD, PhD
joined UMass Chan Medical School faculty in September 2014. Prior to joining UMass Chan, he served as an attending neurologist, in Augusta, Maine, for Maine General Neurology from 2012 to 2014, and was a faculty for Barrow Neurological Institute, from 2008-2012 in Phoenix, Arizona, where he completed his fellowship in neuroimmunology. 

Bomprezzi, MD, and PhD, completed medical school at the Sapienza University of Rome in Rome, Italy. He focused on clinical genetics research at the National Institutes of Health from 1999-2003 before completing his neurology residency at St Joseph’s Hospital in Phoenix, Arizona.  

Bomprezzi, MD, PhD, Research Experience: 
Associations between spinal cord structural disease and MS disease severity.  
 - Optimizing the choice and dosing of immune-modulating therapy in treating neuroinflammation.  
 - Clinical trials with new medications.  
 - Implementing new techniques to assess cognition and to alleviate tremor in patients with MS. 

Bomprezzi, MD, PhD, Clinical Experience:
Fellowship trained in neuroimmunology.  
 - Involved in the treatment of inflammatory disorders of the central nervous system, such as multiple sclerosis, neuromyelitis optica, neurosarcoidosis.

Bomprezzi, MD, PhD, Education Experience: 
Over 15 years of experiene as a faculty member training medical students, residents, fellows, and postdocs.
 - International speaker 

Active/Current Clinical Trials - Conquering Diseases - Search

Roberto Bomprezzi, MD, PhD, publications

Total: 15 results
  • Cervical spondylosis is a risk factor for localized spinal cord lesions in multiple sclerosis

    Thursday, October 22, 2020
    Author(s): Roberto Bomprezzi,Andrew P Chen,Christopher C Hemond
    Source: Clinical neurology and neurosurgery
    CONCLUSIONS: The data from our cohort of MS patients suggest an indirect contribution of cervical spondylosis to disability by increasing the risk of developing localized cord lesions. While further studies are needed to confirm the findings and clarify disease mechanisms, closer attention should be paid to worsening spondylosis in patients with MS.
  • Are randomized, blind clinical trials enough to guide individualized decisions for patients with neurologic diseases?

    Saturday, February 24, 2018
    Author(s): Yazan J Alderazi,Roberto Bomprezzi
    Source: Neurology. Clinical practice
    The practice of medicine relies on the patient-physician relationship, knowledge, and clinical judgment. Randomized controlled trials (RCTs) remain the least biased method for studying the effects of interventions in selected populations and are the only method to control adequately for unknown confounders. However, physicians face the limitations of RCTs on a daily basis as they treat relatively unselected populations and individual patients. We explore the benefits and limitations of RCTs for...
  • Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

    Friday, October 14, 2016
    Author(s): Gavin Giovannoni,Jeffrey A Cohen,Alasdair J Coles,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,David H Margolin,Stephen L Lake,Susan M Kaup,Michael A Panzara,D Alastair S Compston,CARE-MS II Investigators
    Source: Neurology
    CONCLUSIONS: In patients with RRMS and inadequate response to prior disease-modifying therapies, alemtuzumab provides greater benefits than SC IFN-β-1a across several disability outcomes, reflecting improvement of preexisting disabilities.
  • Extended interval dosing of natalizumab in multiple sclerosis

    Saturday, February 27, 2016
    Author(s): L Zhovtis Ryerson,T C Frohman,J Foley,I Kister,B Weinstock-Guttman,C Tornatore,K Pandey,S Donnelly,S Pawate,R Bomprezzi,D Smith,C Kolb,S Qureshi,D Okuda,J Kalina,Z Rimler,R Green,N Monson,T Hoyt,M Bradshaw,J Fallon,E Chamot,M Bucello,S Beh,G Cutter,E Major,J Herbert,E M Frohman
    Source: Journal of neurology, neurosurgery, and psychiatry
    CONCLUSIONS: Dosing intervals up to 8 weeks 5 days did not diminish effectiveness of NTZ therapy. Further monitoring is ongoing to evaluate if the risk of PML is reduced in patients on EID.
  • Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study

    Tuesday, June 23, 2015
    Author(s): Koushik A Govindarajan,Sushmita Datta,Khader M Hasan,Sangbum Choi,Mohammad H Rahbar,Stacey S Cofield,Gary R Cutter,Fred D Lublin,Jerry S Wolinsky,Ponnada A Narayana,MRI Analysis Center at Houston,CombiRx Investigators Group
    Source: Human brain mapping
    A comprehensive analysis of the effect of lesion in-painting on the estimation of cortical thickness using magnetic resonance imaging was performed on a large cohort of 918 relapsing-remitting multiple sclerosis patients who participated in a phase III multicenter clinical trial. An automatic lesion in-painting algorithm was developed and implemented. Cortical thickness was measured using the FreeSurfer pipeline with and without in-painting. The effect of in-painting was evaluated using...
  • Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data

    Friday, March 20, 2015
    Author(s): Sushmita Datta,Terrell D Staewen,Stacy S Cofield,Gary R Cutter,Fred D Lublin,Jerry S Wolinsky,Ponnada A Narayana,MRI Analysis Center at Houston,CombiRx Investigators Group
    Source: Multiple sclerosis and related disorders
    Regional gray matter (GM) atrophy in multiple sclerosis (MS) at disease onset and its temporal variation can provide objective information regarding disease evolution. An automated pipeline for estimating atrophy of various GM structures was developed using tensor based morphometry (TBM) and implemented on a multi-center sub-cohort of 1008 relapsing remitting MS (RRMS) patients enrolled in a Phase 3 clinical trial. Four hundred age and gender matched healthy controls were used for comparison....
  • Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

    Sunday, February 15, 2015
    Author(s): David H Miller,Robert J Fox,J Theodore Phillips,Michael Hutchinson,Eva Havrdova,Mariko Kita,Claudia A M Wheeler-Kingshott,Daniel J Tozer,David G MacManus,Tarek A Yousry,Mary Goodsell,Minhua Yang,Ray Zhang,Vissia Viglietta,Katherine T Dawson,CONFIRM study investigators
    Source: Neurology
    CONCLUSIONS: The robust effects on MRI active lesion counts and total lesion volume in patients with RRMS demonstrate the ability of DMF to exert beneficial effects on inflammatory lesion activity in multiple sclerosis, and support DMF therapy as a valuable new treatment option in RRMS.
  • Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview

    Wednesday, January 14, 2015
    Author(s): Roberto Bomprezzi
    Source: Therapeutic advances in neurological disorders
    Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety and efficacy data generated in Europe from usage of fumaric acid formulations in the latter disease constituted grounds to investigate their effects in MS patients. Dimethyl fumarate (DMF) was found to be the active principle in those formulations and in vitro studies have demonstrated that DMF has immune-modulatory properties exerted through abilities to divert cytokine production toward a Th2 profile,...
  • Extended interval dosing of natalizumab: a two-center, 7-year experience

    Saturday, October 25, 2014
    Author(s): Roberto Bomprezzi,Siddharama Pawate
    Source: Therapeutic advances in neurological disorders
    CONCLUSION: Natalizumab is effective in controlling MS as very few clinical relapses were observed in our dataset. We found that EID did not compromise the treatment effect as measured by relapse rate and no significant breakthrough disease activity was observed. EID is an optional regimen for maintenance natalizumab therapy, but prospective studies are warranted to determine its efficacy.
  • Demyelinating disease and psoriasis: interferon versus dimethyl fumarate

    Sunday, June 08, 2014
    Author(s): Lynn G Howard,Roberto Bomprezzi
    Source: Journal of the neurological sciences
    No abstract
  • Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis

    Tuesday, July 23, 2013
    Author(s): Feng Sun,Shafeeq S Ladha,Li Yang,Qiang Liu,Samuel Xiang-Yu Shi,Ning Su,Roberto Bomprezzi,Fu-Dong Shi
    Source: Muscle & nerve
    CONCLUSIONS: We have characterized a specific subset of B10 cells in MG patients which may serve as a marker for disease activity and responsiveness to immune therapy.
  • Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing

    Tuesday, March 26, 2013
    Author(s): Kasandra Lovette Burgos,Ashkan Javaherian,Roberto Bomprezzi,Layla Ghaffari,Susan Rhodes,Amanda Courtright,Waibhav Tembe,Seungchan Kim,Raghu Metpally,Kendall Van Keuren-Jensen
    Source: RNA (New York, N.Y.)
    There has been a growing interest in using next-generation sequencing (NGS) to profile extracellular small RNAs from the blood and cerebrospinal fluid (CSF) of patients with neurological diseases, CNS tumors, or traumatic brain injury for biomarker discovery. Small sample volumes and samples with low RNA abundance create challenges for downstream small RNA sequencing assays. Plasma, serum, and CSF contain low amounts of total RNA, of which small RNAs make up a fraction. The purpose of this study...
  • Randomized study combining interferon and glatiramer acetate in multiple sclerosis

    Thursday, February 21, 2013
    Author(s): Fred D Lublin,Stacey S Cofield,Gary R Cutter,Robin Conwit,Ponnada A Narayana,Flavia Nelson,Amber R Salter,Tarah Gustafson,Jerry S Wolinsky,CombiRx Investigators
    Source: Annals of neurology
    OBJECTIVE: A double-blind, randomized, controlled study was undertaken to determine whether combined use of interferon β-1a (IFN) 30 μg intramuscularly weekly and glatiramer acetate (GA) 20 mg daily is more efficacious than either agent alone in relapsing-remitting multiple sclerosis.
  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

    Tuesday, November 06, 2012
    Author(s): Jeffrey A Cohen,Alasdair J Coles,Douglas L Arnold,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Elizabeth Fisher,Vesna V Brinar,Gavin Giovannoni,Miroslav Stojanovic,Bella I Ertik,Stephen L Lake,David H Margolin,Michael A Panzara,D Alastair S Compston,CARE-MS I investigators
    Source: Lancet (London, England)
    BACKGROUND: The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.
  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

    Tuesday, November 06, 2012
    Author(s): Alasdair J Coles,Cary L Twyman,Douglas L Arnold,Jeffrey A Cohen,Christian Confavreux,Edward J Fox,Hans-Peter Hartung,Eva Havrdova,Krzysztof W Selmaj,Howard L Weiner,Tamara Miller,Elizabeth Fisher,Rupert Sandbrink,Stephen L Lake,David H Margolin,Pedro Oyuela,Michael A Panzara,D Alastair S Compston,CARE-MS II investigators
    Source: Lancet (London, England)
    BACKGROUND: The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.